Flange Fitting for Agriculture Pipes - Finolex Pipes
Finolex Pipes offers PVC flanges to provide temporary disassembly of a piping system. Visit their website for more information on PVC flange sizes.
Artificial Intelligence in Drug Discovery Market: Opportunities, Challenges, and Strategic Insights Through 2030
Meticulous Research®, a leading global market research firm, has recently released a comprehensive report titled "Artificial Intelligence in Drug Discovery Market by Offering (Software, Services), Application (Target Discovery, Lead Identification, Clinical Testing), Therapy Area (Oncology, Cardiology, Neurodegenerative), Deployment Mode, End User—Global Forecast to 2030."According to this report, the global AI in drug discovery market is anticipated to reach $8.95 billion by 2030, growing at a CAGR of 27.2% during the forecast period from 2024 to 2030. The market's growth is primarily driven by the increasing focus on reducing drug discovery turnaround times, expanding applications of AI in the pharmaceutical sector, rising prevalence of chronic diseases, and significant advancements in artificial intelligence within healthcare. Furthermore, the growing adoption of machine learning (ML) in drug discovery, the emergence of regional start-ups in AI-driven drug discovery, and increasing investments in R&D present substantial opportunities for market expansion.
Market Segmentation and Insights
The study categorizes the global AI in drug discovery market by offering, deployment mode, application, therapeutic area, end user, and geography, while also evaluating industry competitors and analyzing their market shares at both global and regional levels.
Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5429
- By Offering: In 2024, the software segment is expected to dominate the market, benefiting from its high adoption due to its capacity to reduce time and costs in the drug discovery process. This segment includes licensed models, subscription-based services, and software-as-a-service (SaaS) models, all of which generate recurring revenue.
- By Deployment Mode: The cloud & web-based segment is projected to experience the fastest growth during the forecast period. These platforms offer superior accessibility, lower maintenance costs, and extensive storage capacity, making them ideal for managing the large pharmaceutical datasets involved in drug discovery.
- By Application: The lead compound identification segment is expected to hold the largest market share in 2024. As one of the initial and critical stages in drug development, lead compound identification sees significant AI adoption, underscoring its dominant market position.
- By Therapeutic Area: The oncology segment is forecasted to account for the largest market share in 2024, driven by the increasing prevalence of cancer and the growing focus on AI-driven oncology therapies. The global rise in cancer cases and substantial R&D investments in novel cancer therapies are key contributors to this segment's growth.
- By End User: Pharmaceutical and biopharmaceutical companies are anticipated to dominate the market in 2024, supported by high investments in AI and a strong focus on developing AI-based oncology drugs.
Geographic Analysis
Geographically, North America is expected to lead the global AI in drug discovery market in 2024, followed by Europe and Asia-Pacific. The U.S. is projected to hold the largest market share in North America, driven by significant public and private investments in drug discovery, widespread adoption of AI solutions, and the presence of major AI and pharmaceutical companies such as Abbott Laboratories and Pfizer Inc.
Quick Buy – AI in Drug Discovery Market- Global Opportunity Analysis And Industry Forecast (2024-2030), Research Report: https://www.meticulousresearch.com/Checkout/71789081
Key Market Players
The global AI in drug discovery market is characterized by the presence of several key players, including Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrödinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea). These companies play a pivotal role in shaping the market landscape and driving innovation in AI-driven drug discovery.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Please login to comment on this Post